App-Quantinova.ai

Advance Care Planning in Parkinson’s Disease – Are we getting it right?

C. Grose - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Assessing the screening performance of three abbreviated smell tests in Parkinson’s disease

G. Goodwin - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Bayesian Estimation of Gait Cadence from Monocular Video

Y. Peng - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Bilateral vocal cord paralysis associated with idiopathic Parkinson’s disease

D. Brooks - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Biological and Clinical Manifestations of Huntington’s disease in Gene Carriers Very Far from Predicted Onset: The Young Adult Study

P. Zeun - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Huntington's disease

N/A

Cerebellar structural covariance networks in young people with Tourette syndrome

H. Sigurdsson - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Tourette syndrome

N/A

Changes of gait parameters in Parkinson disease (PD) patients who underwent Deep Brain Stimulation (DBS) Surgery: A prospective one year study

V. Karthikeayan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

CHIEF-PD: Cholinesterase Inhibitor to prEvent Falls in Parkinson’s Disease

S. Neumann - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Rivastigmine

Cortical pathology in Glucocerebrosidase mutation carriers with anxiety: An MRI study

E. de Natale - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

Velaglucerase alfa

Deep Brain Stimulation for medically refractory tremor syndromes

A. Macerollo - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Defining time and anatomical specificity of basal ganglia white matter loss in premanifest Huntington’s disease

P. Zeun - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Huntington's disease

N/A

Dendritic cells and brain metabolites in Tourette’s

M. Sarchioto - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Depression

Inositol

Developing A Novel Disease-Specific Psychosis Severity Scale in Parkinson’s disease (Psy-PD): A Pilot Study

Y.M Wan - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Disentangling postural instability-gait difficulties classification model for the prediction of cognitive impairment in de novo Parkinson’s Disease patients

D. Urso - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Mild cognitive impairment

N/A

Does constipation predict cognitive impairment and dementia in de novo Parkinson’s disease patients? A multi-cohort longitudinal data analysis

V. Leta - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Driving in Parkinson’s Disease: A Retrospective Study of Driving and Mobility Assessments

K. Lloyd - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Dyskinesia and bradykinesia severity patterns in Parkinson’s disease using a wearable sensor

D. van Wamelen - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Effect of opicapone and entacapone on daily pattern of motor fluctuations in Parkinson’s disease patients

A. Lees - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

entacapone

Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations

A. Lees - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Emerging motor dysfunction in those at-risk of Parkinson’s disease: 5-year follow-up of PREDICT-PD participants

C. Simonet - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Parkinson's disease

N/A

Filters

45280 Abstracts